---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031996"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:18:52.038119+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics Q3 revenue up 27% to $2.19M; net loss widens to $10.4M

## Summary
- Revenue $2.19M (+27% YoY); sales revenue $1.9M (+11%); gross profit $738K vs $414K.
- Net loss $10.4M ($0.04/sh) vs $4.1M ($0.03/sh); R&D expenses surged 708% to $5.7M.
- Cash $18.0M at Sept 30, 2023 (from $43.9M at Dec 31, 2022); runway into late Q2 2024.
- Dosed first patient in Phase 1/2a trial of [212Pb]VMT-α-NET for neuroendocrine tumors.
- Completed recruitment for first cohort of Phase 1/2a VMT01 trial for melanoma; no serious AEs.

## SEC filing metadata
- accession: 0001437749-23-031996
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774923031996/0001437749-23-031996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774923031996/isr20231113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031996
- JSON: https://secwatch.observer/filing/0001437749-23-031996.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031996.txt

## Key facts
- Earnings Releases
  Perspective Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: issued a press release announcing its financial results for the quarter ended September 30, 2023 and providing recent business highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923031996/0001437749-23-031996-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.